CHMP recommends subcutaneous form of Sanofi’s Sarclisa and four new drugsnews2026-03-27T17:29:48+00:00March 27th, 2026|Endpoints News|
FDA approves Novo Nordisk’s once-weekly insulinnews2026-03-27T13:43:46+00:00March 27th, 2026|Endpoints News|
Post-Hoc: It’s time to make ACIP serious againnews2026-03-26T14:04:48+00:00March 26th, 2026|Endpoints News|
More changes ahead for Takeda with new CEO set to take reinsnews2026-03-25T18:59:59+00:00March 25th, 2026|Endpoints News|
How Seaport is hedging against failure in Phase 2b depression studynews2026-03-25T18:00:28+00:00March 25th, 2026|Endpoints News|
FDA approves Corcept’s Lifyorli for ovarian cancer months earlynews2026-03-25T17:12:25+00:00March 25th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressurenews2026-03-25T15:14:06+00:00March 25th, 2026|Endpoints News|
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblixnews2026-03-25T10:47:34+00:00March 25th, 2026|Endpoints News|
Biotech investors set to meet with key congressional panelnews2026-03-24T12:00:02+00:00March 24th, 2026|Endpoints News|
